Raymond James & Associates Imv Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$2.9 - $4.4 $132,640 - $201,247
-45,738 Closed
0 $0
Q3 2020

Nov 04, 2020
BUY
$2.87 - $5.95 $77,277 - $160,209
26,926 Added 143.13%
45,738 $205,000
Q2 2020

Jul 28, 2020
SELL
$1.52 - $3.63 $7,951 - $18,988
-5,231 Reduced 21.76%
18,812 $58,000
Q1 2020

Apr 21, 2020
BUY
$1.4 - $4.92 $33,660 - $118,291
24,043 New
24,043 $42,000

About IMV Inc.

IMV Quotes by TradingView
  • Ticker IMV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,452,200
  • Description
  • IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is P...
More about IMV
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email